The Toronto Helicobacter pylori Consensus in Context

Gastroenterology

Volumn 151, Issue 1, 2016, Pages 9-12

  Graham, David Y ^a   Laine, Loren ^b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CONSENSUS; EDITORIAL; HELICOBACTER INFECTION; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; HELICOBACTER PYLORI;

CONSENSUS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

EID: 84990038413     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.05.009     Document Type: Editorial

References (21)

1. 1 Institute of Medicine. Clinical practice guidelines we can trust. 2011, The National Academies Press, Washington, DC.
2. 2 Fallone, C.A., Chiba, N., van Zanten, S.V., et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 151 (2016), 51–69.
3. 3 Wenzhen, Y., Yumin, L., Quanlin, G., et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med 49 (2010), 1103–1109.
4. 4 Graham, D.Y., Dore, M.P., Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther, 2016 May 3 [Epub ahead of print].
5. 5 Graham, D.Y., Lee, Y.C., Wu, M.S., Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 12 (2014), 177–186.
6. 6 Liou, J.M., Chen, C.C., Chen, M.J., et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 381 (2013), 205–213.
7. 7 Wu, J.Y., Liou, J.M., Graham, D.Y., Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol 8 (2014), 21–28.
8. 8 Graham, D.Y., Helicobacter pylori update: Gastric cancer, reliable therapy, and possible benefits. Gastroenterology 148 (2015), 719–731.
9. 9 Cosme, A., Montes, M., Martos, M., et al. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clin Microbiol Infect 19 (2013), 379–383.
10. 10 Koletzko, S., Jones, N.L., Goodman, K.J., et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 53 (2011), 230–243.
11. 11 Gold, B.D., Resistance testing for Helicobacter pylori infection: is it finally ready for prime time?. J Pediatr Gastroenterol Nutr 59 (2014), 3–4.
12. 12 Shiota, S., Reddy, R., Alsarraj, A., et al. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol 13 (2015), 1616–1624.
13. 13 Lu, H., Zhang, W., Graham, D.Y., Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol 25 (2013), 1134–1140.
14. 14 Graham, D.Y., Lee, S.Y., How to effectively use bismuth quadruple therapy: The good, the bad, and the ugly. Gastroenterol Clin North Am 44 (2015), 537–563.
15. 15 Zhang, W., Chen, Q., Liang, X., et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 64 (2015), 1715–1720.
16. 16 Dore, M.P., Lu, H., Graham, D.Y., Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 65 (2016), 870–878.
17. 17 Megraud, F., Coenen, S., Versporten, A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62 (2013), 34–42.
18. 18 Ghotaslou, R., Leylabadlo, H.E., Asl, Y.M., Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World J Methodol 5 (2015), 164–174.
19. 19 Thung, I., Aramin, H., Vavinskaya, V., et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 43 (2016), 514–533.
20. 20 Duck, W.M., Sobel, J., Pruckler, J.M., et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 10 (2004), 1088–1094.
21. 21 Scott, D., Weeks, D., Melchers, K., et al. The life and death of Helicobacter pylori. Gut 43 Suppl 1 (1998), S56–S60.